About Management



As President and Chief Executive Officer, Michael Egholm, PhD, leads Standard BioTools in its mission to unleash its next-generation technologies to help drive innovation in the life science industry. Under his direction, Standard BioTools is expected to grow into a best-in-class solutions partner to biopharmaceutical researchers through the expansion of in-house technologies and future acquisitions. 

Michael brings more than 25 years of proven leadership in developing and commercializing innovative technologies that drive success in the discovery and development of biopharmaceuticals. Prior to joining Standard BioTools, he served as the Chief Technology Officer of Danaher Life Sciences as well as the founder and leader of the Danaher Corporation’s (NYSE:DHR) venture fund. During that time, he led Danaher’s Pall Corporation biopharmaceuticals business, where he played a central role in redesigning its go-to-market structure, leading to the company’s multibillion-dollar revenue today.

Prior to Danaher, Michael was the Chief Technology Officer at Roche’s 454 Life Sciences Corporation, the first company to successfully commercialize next-generation sequencing. There, he spearheaded several large, high-profile programs, including the Neanderthal Sequencing project and the sequencing of the first individual human genome. 

An elected member of the Royal Danish Academy of Sciences and Letters, Michael is the named inventor of 40 U.S. patents. While a research associate at the University of Copenhagen, he was lead inventor of peptide nucleic acids (PNA) technology, a synthetic form of DNA, for which he earned his PhD in organic chemistry. More than 2,300 peer-reviewed papers have been published on the properties and uses of PNA, including 42 authored by Michael. He has published more than 100 research papers, with several in the most prestigious peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine

During his personal time, Michael is an avid runner, yogi, and scuba diver and an instrument-rated private pilot.


Alex Kim is Chief Operating Officer of Standard BioTools. Alex has a passion for improving healthcare and in building businesses by bringing together teams and capabilities to accelerate the pace of innovative breakthroughs.

Prior to joining Standard BioTools, Alex was President of Milliken’s Healthcare Division, a leading provider of advanced wound care products for human health, animal health, and sports medicine. He joined Milliken in 2015 initially as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development at Pall Corporation.  And from 2002 to 2012, he worked at Danaher Corporation (NYSE:DHR) in a variety of roles in general management, M&A, and business development. Over his career, Alex has completed over 40 transactions, largely focused on healthcare, medical technology, and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business. In his early career, Alex worked in a variety of engineering design, product development, and marketing/sales support roles. Alex has a BS in Mechanical Engineering from Carnegie Mellon University, an MS In Mechanical Engineering from University of Pittsburgh, and an MBA from Stanford University.

In his free time, Alex enjoys playing golf and tennis, and most importantly, spending time with his family. 


Jeff Black brings over 30 years of experience to Standard BioTools, having served in senior finance leadership roles for seven publicly traded companies. Most recently he was Chief Financial Officer at Apollo Endosurgery, Inc., a medical technology company focused on endoscopic therapies for gastrointestinal conditions and interventional treatment of obesity. While at Apollo, Jeff was part of a new executive team that repositioned the company, secured $175 million in new capital, grew annual revenue by 20%-plus, and increased market capitalization from $85 million to more than $400 million over a two-year period, all culminating in a $650 million sale to Boston Scientific in April 2023.

Prior to Apollo, Jeff was Chief Financial Officer at Alphatec Holdings, Inc. (Nasdaq:ATEC), a medical technology company providing spinal fusion solutions. He played a key role in the successful turnaround of the company, securing nearly $500 million in financing to support accelerated growth, transform the balance sheet, and execute strategic acquisitions. Under his leadership, Alphatec grew from a market capitalization of $20 million to more than $1.5 billion.

Prior to Alphatec, Jeff served as CFO for Applied Proteomics, Inc., AltheaDx, Inc., and Verenium Corporation (formerly Diversa). During his nine-year tenure at Verenium, Jeff played a leadership role in scaling the organization and executing more than $500 million in strategic financing, M&A, and collaborative and licensing transactions, culminating in the successful sale of the company to BASF in 2013.

Jeff began his career in the San Diego office of EY, serving most recently as Audit Manager.

In his free time, Jeff enjoys rucking, soccer, and spending time with his wife and three daughters.


Adam Taich is the Chief Executive Officer at SomaLogic. He has over 20 years of experience in the life sciences and healthcare markets. His career has spanned a diverse set of roles, including general management, operations, commercial, finance, strategy, and corporate development.

Adam joined SomaLogic in late 2021 as Chief Business Officer. In mid-2022, he was appointed to lead the Life Sciences business. Prior to joining SomaLogic, Adam served as the Vice President and General Manager of the Molecular Biology business of Thermo Fisher Scientific. In this role, he was instrumental in standing up the company’s response to supply critical raw materials for COVID-19 as well as managing a complex global P&L with revenues in excess of $1 billion. While at Thermo Fisher, he also led the Protein and Cell Analysis business, Global Services and Support, and strategy and corporate development for the Life Sciences Group, and held a variety of finance leadership roles. He joined Thermo Fisher via its acquisition of Life Technologies. Earlier in his career, he was an Associate in the M&A group at Donaldson, Lufkin & Jenrette in New York City.

Adam received his BA from Miami University in Oxford, OH.

As Senior Vice President and Chief Legal Officer, Agnieszka (Aggie) Gallagher leads Standard BioTools legal and compliance functions in identifying and implementing business-focused solutions while remaining in compliance with all applicable laws and regulations. She is a key member of the Executive Leadership Team (ELT) and provides advice and legal counsel to the Chief Executive Officer, ELT, and Board of Directors to enhance and protect the assets and reputation of the company.

Aggie’s career has allowed her to live and work in many locations across the globe, such as Hong Kong, Switzerland, Germany, and Belgium, where she successfully established legal, compliance, and risk management infrastructures and managed complex multinational government and regulatory relationships in several leading pharmaceutical and biotech corporations, including Pfizer, GSK, Sandoz, Medtronic, and Alnylam Pharmaceuticals. 

Aggie currently lives outside Boston with her husband, her teenage son, and two very large dogs. 


Anders Davas is the Senior Vice President, Global Operations. He was previously Senior Vice President, Operational Excellence of Standard BioTools since April 2022.

Previously, Anders was Vice President Global Manufacturing of Mölnlycke Health Care, a world-leading medical product and solution company. His responsibilities covered development and execution of manufacturing strategy, design of fit-for purpose supply chain and manufacturing footprint, and day-to day running of large-scale manufacturing operations.

Before joining Mölnlycke, Anders was the General Manager and Director at Pall Corporation in the UK. At Pall, he was instrumental in implementing best operational practices and business operating frameworks to drive operational excellence. Prior to joining Pall, Anders held senior leadership positions with Eaton Corporation and Teleflex Inc. 

Anders has over 20 years of proven leadership in complex manufacturing and supply chain settings. He holds an MBA from the Wharton School, a Masters in Operations Management from University of Cambridge, and BSc in Mechanical Engineering from Chalmers University of Technology. 

In his spare time, Anders enjoys boating, skiing, and traveling the world. 

Betsy Jensen

Betsy Jensen leads the Standard BioTools human resources function. She brings over 25 years of experience transforming companies to achieve growth and profitability.

Betsy spent nearly eight years leading human resources and internal communications at several Danaher Corporation subsidiaries including Hach Company, Cepheid, Molecular Devices, and SCIEX, then served most recently as Chief Human Resources Officer at Gibraltar Industries. Throughout her career, Betsy has partnered with businesses to accelerate growth, embrace continuous improvement, provide leadership, and develop strategy and analytics to drive change and advance innovation. Betsy holds a BS in Business Administration with a concentration in Human Resources Management from San Jose State University.

In her free time, Betsy enjoys spending time with family as well as new culinary experiences, gardening, and movies.


David King received his PhD in applied physics from Stanford University and brings many years of proven leadership in research and development in multiple organizations of different sizes. He originally joined Standard BioTools (Fluidigm at the time) in May 2018. Under his leadership, the Microfluidics R&D team quickly developed and brought to market multiple application products, FDA-authorized diagnostics products, and new-generation microfluidics platforms. Prior to joining Standard BioTools, David was Executive Vice President, Product Development at IntegenX, a company focused on integrating fluidics, optics, and biochemistry for decentralized DNA-based human identity testing. David led collaborations with the FBI, Scotland Yard, and many other organizations worldwide to develop a marketplace for IntegenX products. Prior to that, David was Vice President, Product Development at Affymetrix, Inc., and before that Vice President, R&D and Operations at Guava Technologies, where he developed novel flow cytometry platforms and applications. David is an inventor on 37 granted US patents.


As Chief Commercial Officer, Jeremy Davis brings more than two decades of business leadership, driving commercial and operational improvements for world class manufacturing businesses and their associated service centers across the globe. More than half of his career has been spent in President and Chief Executive Officer roles leading transformational change using growth tools and Lean operating principles at publicly traded and private equity-backed companie.

Prior to joining Standard BioTools, Jeremy was President for Culligan’s OEM channel business, during which time he led the business through a rapid growth period of 20%-plus CAGR.  

Before joining Culligan, Jeremy was the CEO for a Grey Mountain Partners portfolio company and held President and Senior Management positions at Danaher Corporation, Meggitt, and Eaton Corporation.

Jeremy earned a BS in Chemical Engineering from the University of Oklahoma and an MBA from the Weatherhead School of Management at Case Western Reserve University. In his free time, Jeremy enjoys spending time outdoors with his wife and two children and his dog. 


As Senior Vice President of Standard BioTools Business System (SBS), Mona Abou-Sayed brings her passion for Lean methodologies and solving problems to enable organizational transformation and drive business growth to the Executive Leadership Team. Throughout her career, Mona has been involved with M&A diligence and integrations. She has also focused on execution with operational excellence for key strategic initiatives by working directly with customers to understand their problems and driving cross-functional alignment.

Prior to joining Standard BioTools, Mona held key leadership positions to drive strategic transformations at Mitel, a global leader for business communications and collaboration solutions. She was most recently a Vice President of Strategy Execution and Continuous Improvement at Mitel, most notably driving an evolution in the Cloud Go To Market model. Also at Mitel, she led a team to deliver a single cloud-based video collaboration tool across the Mitel portfolio, as well as the development and adoption of the Learning & Talent Management framework. Prior to Mitel, Mona held several leadership roles at Tektronix Communications, then a Danaher Corporation company, in customer operations, product management, and most recently leading the Danaher Business System office. 

Mona has a BS in Management Science and an MS in Operations Research from Southern Methodist University. In her spare time, Mona enjoys working out, traveling, and spending quality time with her family.


Shane Bowen, PhD, was previously the Chief Research and Development Officer at SomaLogic and was responsible for all aspects of the company’s technology, scientific, and development functions. He oversaw product innovation across the Core Science, Bioinformatics & Data, Engineering, Software, and Platform Innovation groups.

Prior to joining SomaLogic, Shane held several roles at Illumina, where he was foundational to the development of the chemical patterning technology that delivered commercialization of the $1,000 genome in 2014 as the HiSeq X platform and enabled the trajectory to deliver the $100 genome, commercialized in 2017 as the NovaSeq platform. In 2020, Shane cofounded Palamedrix, serving as President and Chief Executive Officer, leading the charge to build a DNA nanotechnology-based platform for single molecule protein identification and quantification. In 2022, Palamedrix was acquired by SomaLogic and Shane was hired by the company as Vice President of Technology Development.

Shane earned his BS in Physics and Mathematics from the University of San Francisco in 1998. In 2000 he completed his MS in Applied Physics and in 2005 his PhD in Physical Chemistry, both from the University of California San Diego.

In his personal time, Shane enjoys spending time with his wife and daughter. He is also an avid surfer and travels around the globe to find the best waves.


Stephen Williams, MD, PhD, has been the Chief Medical Officer at SomaLogic since 2009, and is responsible for Clinical R&D, Medical Affairs, and Regulatory and Quality. He oversees clinical application of the SomaScan Platform and has also had roles in launching the life sciences commercial business, assay development, and bioinformatics.

Steve previously had an 18-year career at Pfizer, with roles in Experimental Medicine and as the Vice President and Worldwide Head of Clinical Technology. He was also on the National Advisory Council for Biomedical Imaging and Bioengineering at the U.S. National Institutes of Health. He helped launch the Alzheimer’s Disease Neuroimaging Initiative and form the FDA-FNIH-PhRMA biomarker consortium.

Steve has degrees in physiology, medicine, and surgery, and received his doctorate in medicine and physiology from Charing Cross and Westminster Medical School (now a part of Imperial College London). He also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.

In his personal time, Steve likes spending time with his family, walking their three dogs, mountain biking, working out, and constantly fixing his 1954 Triumph TR2.

Unless explicitly and expressly stated otherwise, all products are provided for Research Use Only, not for use in diagnostic procedures. Find more information here.